scholarly journals PET – advanced nuclear imaging technology for medicine

2019 ◽  
Vol 65 (3) ◽  
Author(s):  
Hanna Piwowarska-Bilska ◽  
Aleksandra Supińska ◽  
Jacek Iwanowski ◽  
Adriana Tyczyńska ◽  
Bożena Birkenfeld
Keyword(s):  
Computed Tomography ◽  
Nuclear Medicine ◽  
Single Photon ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
Emission Computed Tomography ◽  
Ct Scanner ◽  
Imaging Technology ◽  
Positron Emission ◽  
Pet Ct

Positron emission tomography (PET) is currently the most advanced diagnostic imaging technology along with well-known techniques like magnetic resonance imaging (MRI) and computed tomography (CT). Tremendous technical progress in engineering, imaging and radiopharmacy has provided the basis for impressive technological advances in the field of nuclear medicine over the past 50 years. Current nuclear medicine can be divided into 2 groups: the classic, which uses gamma-cameras for single photon emission computed tomography (SPECT) imaging, and the more modern PET technique. The clinical PET technique requires: (i) patient administration of the radiopharmaceutical labelled with a positron emitter, (ii) recording of the gamma radiation emitted from the patient’s body with a dedicated PET/ CT scanner, (iii) processing and analysis of recorded images. This article presents the basics of PET technology and research, and describes new technical trends introduced by the leading manufacturers of PET/CT scanners.

scholarly journals The 2020 national diagnostic reference levels for nuclear medicine in Japan

2020 ◽  
Vol 34 (11) ◽  
pp. 799-806
Author(s):  
Koichiro Abe ◽  
Makoto Hosono ◽  
Takayuki Igarashi ◽  
Takashi Iimori ◽  
Masanobu Ishiguro ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Nuclear Medicine ◽  
Radiation Dose ◽  
Single Photon ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Diagnostic Reference Levels ◽  
Reference Levels ◽  
Positron Emission ◽  
Pet Ct

Abstract The diagnostic reference levels (DRLs) are one of several effective tools for optimizing nuclear medicine examinations and reducing patient exposure. With the advances in imaging technology and alterations of examination protocols, the DRLs must be reviewed periodically. The first DRLs in Japan were established in 2015, and since 5 years have passed, it is time to review and revise the DRLs. We conducted a survey to investigate the administered activities of radiopharmaceuticals and the radiation doses of computed tomography (CT) in hybrid CT accompanied by single photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. We distributed a Web-based survey to 915 nuclear medicine facilities throughout Japan and survey responses were provided by 256 nuclear medicine facilities (response rate 28%). We asked for the facility's median actual administered activity and median radiation dose of hybrid CT when SPECT/CT or PET/CT was performed for patients with standard habitus in the standard protocol of the facility for each nuclear medicine examination. We determined the new DRLs based on the 75th percentile referring to the 2015 DRLs, drug package inserts, and updated guidelines. The 2020 DRLs are almost the same as the 2015 DRLs, but for the relatively long-lived radionuclides, the DRLs are set low due to the changes in the Japanese delivery system. There are no items set higher than the previous values. Although the DRLs determined this time are roughly equivalent to the DRLs used in the US, overall they tend to be higher than the European DRLs. The DRLs of the radiation dose of CT in hybrid CT vary widely depending on each imaging site and the purpose of the examination.

scholarly journals A Nordic survey of CT doses in hybrid PET/CT and SPECT/CT examinations

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Natalie A. Bebbington ◽  
Bryan T. Haddock ◽  
Henrik Bertilsson ◽  
Eero Hippeläinen ◽  
Ellen M. Husby ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Single Photon ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Single Photon Emission ◽  
Positron Emission ◽  
Pet Ct ◽  
Clinical Purpose ◽  
Single Photon Emission Computed ◽  
Photon Emission Computed Tomography

Abstract Background Computed tomography (CT) scans are routinely performed in positron emission tomography (PET) and single photon emission computed tomography (SPECT) examinations globally, yet few surveys have been conducted to gather national diagnostic reference level (NDRL) data for CT radiation doses in positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/computed tomography (SPECT/CT). In this first Nordic-wide study of CT doses in hybrid imaging, Nordic NDRL CT doses are suggested for PET/CT and SPECT/CT examinations specific to the clinical purpose of CT, and the scope for optimisation is evaluated. Data on hybrid imaging CT exposures and clinical purpose of CT were gathered for 5 PET/CT and 8 SPECT/CT examinations via designed booklet. For each included dataset for a given facility and scanner type, the computed tomography dose index by volume (CTDIvol) and dose length product (DLP) was interpolated for a 75-kg person (referred to as CTDIvol,75kg and DLP75kg). Suggested NDRL (75th percentile) and achievable doses (50th percentile) were determined for CTDIvol,75kg and DLP75kg according to clinical purpose of CT. Differences in maximum and minimum doses (derived for a 75-kg patient) between facilities were also calculated for each examination and clinical purpose. Results Data were processed from 83 scanners from 43 facilities. Data were sufficient to suggest Nordic NDRL CT doses for the following: PET/CT oncology (localisation/characterisation, 15 systems); infection/inflammation (localisation/characterisation, 13 systems); brain (attenuation correction (AC) only, 11 systems); cardiac PET/CT and SPECT/CT (AC only, 30 systems); SPECT/CT lung (localisation/characterisation, 12 systems); bone (localisation/characterisation, 30 systems); and parathyroid (localisation/characterisation, 13 systems). Great variations in dose were seen for all aforementioned examinations. Greatest differences in DLP75kg for each examination, specific to clinical purpose, were as follows: SPECT/CT lung AC only (27.4); PET/CT and SPECT/CT cardiac AC only (19.6); infection/inflammation AC only (18.1); PET/CT brain localisation/characterisation (16.8); SPECT/CT bone localisation/characterisation (10.0); PET/CT oncology AC only (9.0); and SPECT/CT parathyroid localisation/characterisation (7.8). Conclusions Suggested Nordic NDRL CT doses are presented according to clinical purpose of CT for PET/CT oncology, infection/inflammation, brain, PET/CT and SPECT/CT cardiac, and SPECT/CT lung, bone, and parathyroid. The large variation in doses suggests great scope for optimisation in all 8 examinations.

scholarly journals Nuclear Imaging of Glucose Metabolism: Beyond 18F-FDG

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Han Feng ◽  
Xiaobo Wang ◽  
Jian Chen ◽  
Jing Cui ◽  
Tang Gao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Tumor Imaging ◽  
Single Photon ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
Emission Tomography ◽  
Metabolic Imaging ◽  
Emission Computed Tomography ◽  
Positron Emission

Glucose homeostasis plays a key role in numerous fundamental aspects of life, and its dysregulation is associated with many important diseases such as cancer. The atypical glucose metabolic phenomenon, known as the Warburg effect, has been recognized as a hallmark of cancer and serves as a promising target for tumor specific imaging. At present, 2-deoxy-2-[18F]fluoro-glucose (18F-FDG)-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for this purpose. The powerful impact of 18F-FDG has prompted intensive research efforts into other glucose-based radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging. Currently, glucose and its analogues have been labeled with various radionuclides such as 99mTc, 111In, 18F, 68Ga, and 64Cu and have been successfully investigated for tumor metabolic imaging in many preclinical studies. Moreover, 99mTc-ECDG has advanced into its early clinical trials and brings a new era of tumor imaging beyond 18F-FDG. In this review, preclinical and early clinical development of glucose-based radiopharmaceuticals for tumor metabolic imaging will be summarized.

scholarly journals Theranostics: New Era in Nuclear Medicine and Radiopharmaceuticals

2021 ◽  
Author(s):  
Chanchal Deep Kaur ◽  
Koushlesh Kumar Mishra ◽  
Anil Sahu ◽  
Rajnikant Panik ◽  
Pankaj Kashyap ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Single Photon ◽  
Inflammatory Diseases ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
High Energy ◽  
Future Perspective ◽  
Emission Computed Tomography ◽  
Positron Emission ◽  
Current Scenario

Malignancy and many inflammatory diseases have become a major concern for mankind over the years. The conventional therapy of these diseases lacks the effectiveness of the better diagnosis and targeted treatment of these diseases, but nuclear medicine can be regarded as a savior in the current scenario. Over the years, radioactivity of radioisotopes has been employed for treatment of many diseases. Nuclear medicines came up with radiopharmaceuticals that impart the ability to destroy specific diseased cells with high-energy-emitting radionuclides. Moreover, the emergence of theranostics, which is a combination of single drug used both for diagnostic as well as therapeutic purpose, has added a new feather in the field of nuclear medicines for providing a specific and personalized treatment to the patient. The current chapter discusses about techniques used for imaging of these radionuclides for better therapy and diagnosis of the root cause of the concerned disease by positron emission tomography (PET)/CT and single photon emission computed tomography (SPECT)/CT as well as the advantages and disadvantages associated with them. It also describes about applications of theranostics and nuclear imaging in cancer treatment and their future perspective.

scholarly journals MODERN TECHNOLOGIES OF NUCLEAR MEDICINE IN DIAGNOSIS OF BRAIN TUMORS (LITERATURE REVIEW)

2018 ◽  
Vol 5 (5) ◽  
pp. 37-45
Author(s):  
N. A. Kostenikov ◽  
A. V. Pozdnyakov ◽  
A. A. Stanzhevskiy ◽  
A. A. Mihetko ◽  
Yu. R. Iliuschenko
Keyword(s):  
Brain Tumors ◽  
Single Photon ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
Pathological Process ◽  
Emission Computed Tomography ◽  
Biochemical Processes ◽  
Positron Emission ◽  
Tumor Lesion ◽  
Pet Ct

The review presents an analysis of the literature on the diagnosis of brain tumors and the study of their structural and biological features based on application of nuclear imaging: single photon emission computed tomography (SPECT) and positron emission tomography (PET) with different radiopharmaceuticals (RPHs), especially amino acids (11C-L-methionine and 18F-FET). It is shown PET-CT and SPECT allow to noninvasively study the most important biochemical processes underlying the oncogenesis. The obtained data can be crucial for an early detection of tumor lesion, staging the pathological process, personalization of treatment, evaluation of the efficiency of therapy and prognosis of the oncologic disease outcome.

scholarly journals Novel Imaging Techniques for Heart Failure

2016 ◽  
Vol 2 (1) ◽  
pp. 27 ◽  
Author(s):  
Josep L Melero-Ferrer ◽  
Raquel López-Vilella ◽  
Herminio Morillas-Climent ◽  
Jorge Sanz-Sánchez ◽  
Ignacio J Sánchez-Lázaro ◽  
...  
Keyword(s):  
Heart Failure ◽  
Computed Tomography ◽  
Single Photon ◽  
Imaging Techniques ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
Imaging Modalities ◽  
Emission Computed Tomography ◽  
Main Role ◽  
Positron Emission

Imaging techniques play a main role in heart failure (HF) diagnosis, assessment of aetiology and treatment guidance. Echocardiography is the method of choice for its availability, cost and it provides most of the information required for the management and follow up of HF patients. Other non-invasive cardiac imaging modalities, such as cardiovascular magnetic resonance (CMR), nuclear imaging-positron emission tomography (PET) and single-photon emission computed tomography (SPECT) and computed tomography (CT) could provide additional aetiological, prognostic and therapeutic information, especially in selected populations. This article reviews current indications and possible future applications of imaging modalities to improve the management of HF patients.

Computerized Tomography (CT) Updates and Challenges in Diagnosis of Bone Metastases During Prostate Cancer

2020 ◽  
Vol 16 (5) ◽  
pp. 565-571
Author(s):  
Jinguo Zhang ◽  
Guanzhong Zhai ◽  
Bin Yang ◽  
Zhenhe Liu
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Bone Metastases ◽  
Computerized Tomography ◽  
Single Photon ◽  
Photon Emission ◽  
Major Complication ◽  
Tracer Uptake ◽  
Emission Computed Tomography ◽  
Pet Ct

Prostate cancer is one of the most common cancers in men. This cancer is often associated with indolent tumors with little or no lethal potential. Some of the patients with aggressive prostate cancer have increased morbidity and early deaths. A major complication in advanced prostate cancer is bone metastasis that mainly results in pain, pathological fractures, and compression of spinal nerves. These complications in turn cause severe pain radiating to the extremities and possibly sensory as well as motor disturbances. Further, in patients with a high risk of metastases, treatment is limited to palliative therapies. Therefore, accurate methods for the detection of bone metastases are essential. Technical advances such as single-photon emission computed tomography/ computed tomography (SPECT/CT) have emerged after the introduction of bone scans. These advanced methods allow tomographic image acquisition and help in attenuation correction with anatomical co-localization. The use of positron emission tomography/CT (PET/CT) scanners is also on the rise. These PET scanners are mainly utilized with 18F-sodium-fluoride (NaF), in order to visualize the skeleton and possible changes. Moreover, NaF PET/CT is associated with higher tracer uptake, increased target-to-background ratio and has a higher spatial resolution. However, these newer technologies have not been adopted in clinical guidelines due to lack of definite evidence in support of their use in bone metastases cases. The present review article is focused on current perspectives and challenges of computerized tomography (CT) applications in cases of bone metastases during prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document